The United Nations Office at Geneva
Multimedia Newsroom
Edited News | WHO , UNOG , UNITED NATIONS
Bi-weekly Press Briefing: Regeneron COVID-19 Treatment - WHO
WHO back Regeneron COVID-19 drug cocktail, but calls for access and reduction on price
The Regeneron antibody-drug cocktail – casirivimab and imdevimab – has been added to the World Health Organization’s (WHO) list of treatments for people with COVID-19, the UN agency said on Friday, before underscoring the need for lower prices and equitable distribution.
“This is a major breakthrough in the care of COVID-19 patients” said Dr Janet Diaz, WHO head of clinical care. “This is our first recommendation for a therapeutic for those patients with mild, moderate disease,” she said, because it reduces “the need for hospitalisation if they are at high risk”.
WHO’s conditional recommendations are for use of the drug combination on patients who were not severely ill but at high risk of being admitted to hospital with COVID-19, or those with severe cases of the disease and no existing antibodies.
“Giving them this additional antibody seems to show an effect. And what effect is that? A reduction in mortality” Dr Diaz told a briefing in Geneva.
The antibody therapy was granted emergency use authorization in the United States November last year after it was used to treat former President Donald Trump when he was admitted to hospital with COVID-19.
The United Kingdom has also approved Regeneron, while it is under review in Europe. The WHO recommendations were largely based on data from a British study of 9,000 patients in June which found that the therapy reduced deaths in hospitalised patients whose own immune systems had failed to produce a response.
“We are taking the information (from the UK study) and generalizing it to other persons,” said Dr Diaz. “We saw there was a benefit we thought was meaningful.” The treatment has been on the market for decades to treat many other diseases, including cancers. It is based on a class of drugs called monoclonal antibodies which mimic natural antibodies produced by the human body to fight off infections.
Swiss drugmaker Roche has been working in partnership with Regeneron, which holds the patent, to produce the antibody treatment. Dr Diaz urged Regeneron to lower the drug’s price and work on equitable distribution worldwide: “We know that the life-saving benefits and the benefits for patients with COVID-19 is significant and requires action.” Dr Diaz added that UNITAID, an international health agency, was negotiating directly with Roche for lower prices and equitable distribution across all parts of the world, “including low and middle-income countries”.
WHO has also been in discussions with the company for a donation and distribution of the drug through UN Children’s Fund UNICEF, following an allocation criteria set by the health agency. “We are working together with the company so we can address these very important issues so we can have equitable access” she said.
In a statement, WHO said in parallel it had “launched a call to manufacturers who may wish to submit their products for pre-qualification, which would allow for a ramping-up of production and therefore greater availability of the treatment and expanded access. ACT-A partners are also working with WHO on an equitable access framework for recommended COVID-19 therapeutics”. On that subject, Dr Diaz added that “there are bottlenecks and we are aware of those. WHO has launched the pre-qualification expression of interest call so that the manufacturing companies can start to submit their dossiers to WHO”.
ends
STORY: Regeneron COVID-19 Treatment - WHO
TRT: 2’18’’
SOURCE: UNTV CH
LANGUAGE: ENGLISH
ASPECT RATIO: 16:19
DATELINE: 24 Sept 2021, GENEVA, Switzerland
SHOTLIST
- Exterior wide shot, United Nations flag alley.
- Wide shot, inside the bi-weekly press conference room, participants.
- SOUNDBITE (English): Dr Janet Diaz, Head of Clinical Care, World Health Organization (WHO): “So this is a major breakthrough in the care of COVID-19 patients, we have expanded our tools to treat patients with covid-19 and this is our first recommendation for a therapeutic for those patients with mild, moderate disease because of the risk of reducing the need for hospitalization if they are at high risk.”
- Medium shot, participant attending the press briefing.
- SOUNDBITE (English): Dr Janet Diaz, Head of Clinical Care, World Health Organization (WHO): “The first recommendation is a conditional recommendation for use in patients who have non severe COVID-19, so those are patients that are mild or moderate and can be seen in the outpatient setting, but it's on the condition that patients are at the higher risk for severe disease. So not for all the patients, but those at the highest risk.”
- Medium shot, participant attending the briefing.
- SOUNDBITE (English): Dr Janet Diaz, Head of Clinical Care, World Health Organization (WHO): “The second recommendation is a conditional recommendation for patients with severe and critical COVID-19, so those are the sicker patients in the hospital on oxygen, on corticosteroids. The condition here is for those patients that are sero-negative. That means on a serology test at that moment, they have not yet mounted their own antibody response. So giving them this additional antibody seems to show an effect. And what effect is that? A reduction in mortality.”
- Wide shot, speakers at podium and briefing broadcast on large-screen TV.
- SOUNDBITE (English): Dr Janet Diaz, Head of Clinical Care, World Health Organization (WHO): “It is true right now there's limited availability and the cost is high for this monoclonal antibody cocktail. However, with this new recommendation, we know that the life-saving benefits and the benefits for patients with COVID-19 is significant and requires action.”
- Medium shot, participant attending the briefing, podium speaker to rear.
- SOUNDBITE (English): Dr Janet Diaz, Head of Clinical Care, World Health Organization (WHO): “At this time, through the ACT aid mechanism UNITAID is negotiating directly with Roche pharmaceutical companies about manufacturing drugs for lower prices, as you have just described, is very important and equitable distribution across all the regions, including low and middle-income countries.”
- Wide shot, briefing room, the three main speakers of the briefing.
- Medium shot, participants in foreground and to rear.
- Wide shot, press briefing room.
Similar Stories
2
1
2
Press Conferences , Edited News | HRC , OHCHR
The Iranian Government has continued to ramp up efforts to restrict the rights of civilians including young children as part of a concerted effort to crush dissent, investigators mandated by the Human Rights Council insisted on Friday.
2
1
1
Press Conferences , Edited News | HRC
Senior human rights investigators reporting to the Human Rights Council alleged on Thursday that sexual and gender-based violence by Israeli security forces against Palestinian men, women and children have been increasingly used “as a method of war” following the 7 October 2023 attacks that sparked the Gaza war.
1
1
1
Edited News | UNICEF
Bangladesh: Humanitarians describe ‘extreme desperation’ as aid cuts deepen Rohingya children’s suffering
In Bangladesh’s Cox’s Bazar refugee settlements, child malnutrition has surged and cuts in aid funding risk creating a humanitarian “catastrophe”, the UN Children’s Fund (UNICEF) warned on Tuesday.
1
1
1
Edited News | OHCHR , UNOG
The UN Human Rights Office on Tuesday gave an update on the situation in Syria’s coastal region as reports continue to emerge of the distressing scale of violence there since 6 March.
1
1
1
Edited News | UNHCR
The aid response in Burundi to the crisis in neighbouring Democratic Republic of the Congo (DRC) “is literally buckling”, the UN refugee agency, UNHCR, warned on Friday, as it relayed dramatic testimonies from people forced to flee the unchecked advance of Rwanda-backed M23 rebels.
1
1
1
Edited News | UNHCR
Close to 80,000 have fled DR Congo amid fighting, sexual violence: UNHCR
In the eastern Democratic Republic of the Congo (DRC), insecurity and horrific sexual violence have pushed tens of thousands to flee across borders with no sign of the exodus stopping, the UN refugee agency (UNHCR) said on Tuesday.
1
1
1
Edited News | OHCHR , UNOG
UN Human Rights Chief Volker Türk on Monday delivered his global update to the Human Rights Council, highlighting key issues and trends, and the human rights situation in more than 30 countries.
1
1
1
Edited News | OHCHR
The UN Human Rights Chief Volker Türk told the Human Rights Council in Geneva that the human rights situation in Myanmar was among the worst in the world.
1
1
1
Edited News | UNICEF
Haiti: Massive surge in child armed group recruitment – UNICEF
The ongoing emergency in Haiti is crushing children’s chances of an education and a better future as scores of youngsters are recruited by heavily armed and violent gangs, the UN Children’s Fund (UNICEF) warned on Friday.
1
1
1
Edited News | OHCHR , UNOG
UN High Commissioner for Human Rights Volker Türk today called on UN member states to act with urgency towards a ceasefire and to ease the suffering of the Sudanese people.
1
1
1
Edited News | OHCHR , UNOG
“We are at an inflection point in the crisis in the Occupied Palestinian Territory,” the UN Human Rights Chief Volker Türk told the Human Rights Council in Geneva.
1
1
1
Edited News | HRC
Investigators tasked by the UN Human Rights Council to track alleged grave abuses of power by top Nicaraguan officials on Wednesday insisted that the International Court of Justice should prosecute what they called the systematic and systemic repression of the country’s people.